Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Bispecific Antibodies in the Treatment of Multiple Myeloma: Expert and Patient Perspectives : Episode 7

Discussing Consent for Supportive Care Agents with Patients with Multiple Myeloma

February 22, 2023
By Ajai Chari, MD
Annel Urena
  • Kiah Purcell

Video

Nurse Practitioner Kiah Purcell explains how she discusses supportive care agents with patients receiving a BCMA-targeting bispecific for multiple myeloma in case a patient experiences cytokine release syndrome.

EP: 1.A Patient’s Experience With a Multiple Myeloma Diagnosis

EP: 2.Resources for Patient Education

EP: 3.Patient Experience With Treatment for Multiple Myeloma and Clinical Trial Participation

EP: 4.The Role of Teclistamab in Multiple Myeloma

EP: 5.Process of Administering Teclistamab and Other Bispecific Agents

EP: 6.Step-Up Doses in Patients Receiving Teclistamab for Multiple Myeloma

Now Viewing

EP: 7.Discussing Consent for Supportive Care Agents with Patients with Multiple Myeloma

EP: 8.Advice to Patients with Multiple Myeloma Facing Hospital Admission For Teclistamab Therapy

EP: 9.Counseling Patients Receiving Teclistamab for Multiple Myeloma on COVID Precautions

EP: 10.Counseling Patients with Multiple Myeloma on the Infection Risks of BCMA-Targeting Bispecifics

EP: 11.CAR T-Cell Therapy in Multiple Myeloma and Quality of Life

EP: 12.Advice for Patients, Nurse Practitioners, and Community Oncologists on Teclistamab Therapy in Multiple Myeloma

EP: 13.Recap: Teclistamab in Multiple Myeloma: A Patient’s Journey

Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Related Content
Advertisement

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 10th 2025
Article

According to Sundar Jagannath, MBBS, the cure for multiple myeloma was observed in patients who were cancer free for 5 years without maintenance therapy.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


In unweighted analyses, significant PFS improvements were observed, highlighting the differences in restricted mean survival time of 6.95 months.

Elranatamab and MagnetisMM-3 Results Are Superior to Real-World Multiple Myeloma Outcomes

Tim Cortese
August 24th 2025
Article

An observational study reported that results with elranatamab for patients with RRMM from the MagnetisMM-3 trial were superior to what was observed across 5 centers in the UK.


Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.


Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.

Talquetamab Bridging Strategy Appears Feasible in R/R Multiple Myeloma

Russ Conroy
August 20th 2025
Article

Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.


Therapy with anti-CD38 monoclonal antibodies significantly increased the minimal residual disease–negative rate.

Further Research on Anti-CD38 mAbs Warranted in Multiple Myeloma

Tim Cortese
August 19th 2025
Article

A systematic review of 8 randomized trials showed that anti-CD38 monoclonal antibodies did not improve overall survival in high-risk subgroups.

Related Content
Advertisement

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 10th 2025
Article

According to Sundar Jagannath, MBBS, the cure for multiple myeloma was observed in patients who were cancer free for 5 years without maintenance therapy.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


In unweighted analyses, significant PFS improvements were observed, highlighting the differences in restricted mean survival time of 6.95 months.

Elranatamab and MagnetisMM-3 Results Are Superior to Real-World Multiple Myeloma Outcomes

Tim Cortese
August 24th 2025
Article

An observational study reported that results with elranatamab for patients with RRMM from the MagnetisMM-3 trial were superior to what was observed across 5 centers in the UK.


Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.


Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.

Talquetamab Bridging Strategy Appears Feasible in R/R Multiple Myeloma

Russ Conroy
August 20th 2025
Article

Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.


Therapy with anti-CD38 monoclonal antibodies significantly increased the minimal residual disease–negative rate.

Further Research on Anti-CD38 mAbs Warranted in Multiple Myeloma

Tim Cortese
August 19th 2025
Article

A systematic review of 8 randomized trials showed that anti-CD38 monoclonal antibodies did not improve overall survival in high-risk subgroups.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.